A prospective study assessing Delta NT-proBNP predicts cardiotoxicity in HER2-positive breast cancer patients treated with trastuzumab
Latest Information Update: 03 Sep 2021
At a glance
- Drugs Trastuzumab (Primary) ; Trastuzumab (Primary) ; ACE inhibitors; Beta-adrenergic receptor antagonists; Cyclophosphamide; Docetaxel; Epirubicin; Fluorouracil; Paclitaxel; Pertuzumab
- Indications Advanced breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Adverse reactions
- 03 Sep 2021 New trial record